# To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine

> **NCT00207168** · PHASE4 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 120 (—)

## Conditions studied

- AIDS

## Interventions

- **BEHAVIORAL:** Compliance

## Key facts

- **NCT ID:** NCT00207168
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-04
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 120 (—)
- **Last updated:** 2011-04-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207168, "To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00207168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*